The Critical Medicines Act (CMA) addresses supply chain vulnerabilities by redefining procurement criteria, emphasizing quality, security, and environmental standards. European manufacturers gain ...
As a part of its CPHI Frankfurt 2025 coverage, Pharmaceutical Technology ® interviewed Sriman Banerjee, PhD, executive ...
In the first part of this interview, Romanski tells PharmTech Group that while the field of oral dosage forms has not grown ...
In this PharmTech video feature, we highlight the week’s industry news in an easy-to-consume, fun format. New roundups will ...
As Thermo Fisher’s Jennifer Cannon explains in this first part of a two-part interview, the collaboration is intended to help ...
Sustainability in pharmaceutical manufacturing has become a prominent reason for certain decisions made by pharmaceutical ...
CPHI Pharma Awards 2025 recognized innovations in bio/pharmaceutical development, emphasizing sustainability, drug delivery, ...
In this part 2 of a 2-part interview regarding the presentation “Beyond Traditional Markets: The Strategic Importance of ...
Maggie Saykali, Cefic, explains that Western pharma vulnerability stems from market loss to Asia, caused largely by ...
At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb ...
AI and accelerated computing are transforming the bio/pharmaceutical sector by addressing organizational, technological, and ...
J.D. Mowery, Bora, says tariffs localize biopharma supply chains, the "biotech freeze" mandates robust data, and AI rapidly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback